乌鸦传媒

Neoadjuvant therapy that resulted in pathologic complete response (pCR) reduced the risk of breast cancer recurrence by 80%, pooled data from a phase II clinical trial platform showed.

The results held up across all breast cancer subtypes and treatment regimens, which included nine novel combinations. About a third of patients achieved pCR with neoadjuvant therapy, and those patients had 3-year event-free survival (EFS) and distant recurrence-free survival (DRFS) rates of about 95%.

Despite the strong association between neoadjuvant therapy and pCR, however, the long-term implications remain unclear, investigators in the trial consortium acknowledged in .

"The strength of the I-SPY2 study is that it shows that pCR, regardless of high-risk subtype and type of treatment and across nine investigational targeted biologics, is associated with a much better outcome for individuals who achieve pCR," Laura J. Esserman, MD, of the University of California San Francisco, and co-authors wrote of their findings. "Larger confirmatory neoadjuvant trials will be able to generate sufficient data to establish whether pCR can be considered a validated surrogate of EFS.

"Perhaps more importantly, these data should drive and inspire us to think about how to maximize the chance that each individual can achieve pCR. These data provide a clear experimental rationale for serial adjustments to systemic therapy prior to surgery with therapies directed at specific subtypes," the researchers said.

The analysis demonstrated a "strong individual-level association between pCR and the survival endpoints," according to the authors of an , Yu Shyr, PhD, of Vanderbilt University School of Medicine in Nashville (and associate editor of statistics for JAMA Oncology), and Derek Shyr, MS, of the Harvard T.H. Chan School of Public Health in Boston. However, they added, the data remained insufficient to serve as validation of pCR as a surrogate outcome for EFS or DRFS.

To prove that a surrogate endpoint (pCR, in this case) is equivalent to a true endpoint, studies of the endpoint must demonstrate two types of associations: the I-association (between the surrogate and true endpoint) and the T-association (effect of treatment on the surrogate and on the true endpoint). The T-association is particularly challenging, requiring trial-level data with a sufficient number of patients and number of events per treatment type, the editorialists explained.

"Unfortunately, the I-SPY2 trial has a small number of patients and events per treatment type, making it difficult to evaluate T-association," Shyr and Shyr continued. "In addition, the small number of events would have translated to large confidence limits around the summary measures of trial-level association owing to the large sampling error for each data point in a trial-level analysis."

Offering a potential example of a surrogate endpoint gone awry, the editorialists noted that the Prostate Cancer Prevention Trial with finasteride used the surrogate endpoint of biopsy-proven prostate cancer at 7 years, instead of a "true" endpoint, such as elimination of symptomatic disease or reduced mortality. Use of the surrogate reduced the required sample size by 50,000 and showed a significant decrease in the incidence of biopsy-proven prostate cancer.

However, further research showed that finasteride reduced the incidence of biopsy-proven prostate cancer because of its effect on prostate-specific antigen levels, which altered the biopsy sampling pattern and affected the false-positive rate.

"Thus, it is possible that finasteride did not have any effect on the true endpoint, making it difficult to conclude the effectiveness of finasteride based on the surrogate endpoint," the editorialists wrote.

Investigators in the I-SPY2 clinical trial platform evaluate novel therapies in combination with standard chemotherapy in small phase II trials of neoadjuvant therapy for high-risk early breast cancer. The overarching goal of the research program is to identify regimens that have a high likelihood of achieving positive results in a phase III randomized trial. The phase II trials have a uniform design, including a primary endpoint of pCR (ypT0/is, ypN0).

Esserman and colleagues examined the relationship between pCR and 3-year outcomes (EFS and DRFS) in the first 950 randomized patients, including patients allocated to control groups. For most patients, control therapy consisted of 12 weekly cycles of paclitaxel followed by four cycles of doxorubicin and cyclophosphamide. Patients with HER2-positive breast cancer received weekly trastuzumab (Herceptin) plus paclitaxel.

The analysis included patients randomized from March 2010 through 2016, with follow-up data to Feb. 26, 2019. Overall, 34.7% of patients achieved a pCR with assigned treatment. Analysis of baseline characteristics showed no difference between patients who had a pCR and those who did not.

The 3-year EFS and DRFS rates were 95% for patients who achieved pCR. Comparison of patients with and without pCR yielded hazard ratios of 0.19 (95% CI 0.12-0.31) for EFS and 0.21 for DRFS (95% CI 0.13-0.34). Values for EFS ranged from 0.14 to 0.18 across different breast cancer subtypes and 0.10 to 0.20 for DRFS.

Comment